Clinical characteristics of patients with SLE divided according to the presence of serum anti-RLIP76 IgG immunoreactivity
| Characteristics . | Patients withanti-RLIP76 IgG, n = 10 . | Patients without anti-RLIP76 IgG,n = 30 . | P . |
|---|---|---|---|
| Median age, y (range) | 36 (19-44) | 41 (26-71) | .03 |
| Sex, M/F | 0/10 | 5/25 | > .05 |
| Median disease duration, y (range) | 4 (0.5-24) | 7 (0.4-22) | > .05 |
| Median SLEDAI (range) | 0 (0-18) | 2 (0-25) | > .05 |
| Skin lesions, % | 60 | 46.6 | > .05 |
| Arthrites, % | 80 | 66.6 | > .05 |
| Neuropsychiatric manifestations, % | 30 | 26.6 | > .05 |
| Kidney involvement, % | 20 | 30.0 | > .05 |
| Cytopenia, % | 70 | 73.3 | > .05 |
| Serositis, % | 20 | 36.7 | > .05 |
| Antiphospholipid syndrome, % | 20 | 36.7 | > .05 |
| Characteristics . | Patients withanti-RLIP76 IgG, n = 10 . | Patients without anti-RLIP76 IgG,n = 30 . | P . |
|---|---|---|---|
| Median age, y (range) | 36 (19-44) | 41 (26-71) | .03 |
| Sex, M/F | 0/10 | 5/25 | > .05 |
| Median disease duration, y (range) | 4 (0.5-24) | 7 (0.4-22) | > .05 |
| Median SLEDAI (range) | 0 (0-18) | 2 (0-25) | > .05 |
| Skin lesions, % | 60 | 46.6 | > .05 |
| Arthrites, % | 80 | 66.6 | > .05 |
| Neuropsychiatric manifestations, % | 30 | 26.6 | > .05 |
| Kidney involvement, % | 20 | 30.0 | > .05 |
| Cytopenia, % | 70 | 73.3 | > .05 |
| Serositis, % | 20 | 36.7 | > .05 |
| Antiphospholipid syndrome, % | 20 | 36.7 | > .05 |